NASDAQ:SGMO - Sangamo Therapeutics Stock Price, Price Target & More

Get Started

$16.00 +0.35 (+2.24 %)

(As of 05/24/2018 02:30 AM ET)

Previous Close$15.65

Today's Range$15.55 - $16.20

52-Week Range$6.55 - $27.50

Volume1.48 million shs

Average Volume2.33 million shs

Market Capitalization$1.57 billion

P/E Ratio-22.86

Dividend YieldN/A

Beta2.83

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:SGMO

CUSIP80067710

Webwww.sangamo.com

Phone510-970-6000

Debt

Debt-to-Equity Ratio0.14

Current Ratio4.78

Quick Ratio4.78

Price-To-Earnings

Trailing P/E Ratio-22.86

Forward P/E Ratio-29.63

P/E GrowthN/A

Sales & Book Value

Annual Sales$36.57 million

Price / Sales44.41

Cash FlowN/A

Price / CashN/A

Book Value$1.80 per share

Price / Book8.89

Profitability

EPS (Most Recent Fiscal Year)($0.70)

Net Income$-54,560,000.00

Net Margins-126.96%

Return on Equity-30.96%

Return on Assets-20.75%

Miscellaneous

Employees182

Outstanding Shares101,500,000

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics Inc (NASDAQ:SGMO) released its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of $0.29 by $0.52. The biopharmaceutical company earned $12.60 million during the quarter, compared to the consensus estimate of $53.09 million. Sangamo Therapeutics had a negative net margin of 126.96% and a negative return on equity of 30.96%. Sangamo Therapeutics's quarterly revenue was up 270.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.23) earnings per share. View Sangamo Therapeutics' Earnings History.

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Sangamo Therapeutics.

What price target have analysts set for SGMO?

5 brokerages have issued 1 year target prices for Sangamo Therapeutics' shares. Their forecasts range from $8.00 to $30.00. On average, they expect Sangamo Therapeutics' share price to reach $22.20 in the next year. View Analyst Ratings for Sangamo Therapeutics.

What are Wall Street analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:

1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (5/16/2018)
2. Wedbush analysts commented, "We traveled with VBI management last week in Boston and noted good reception and enthusiasm around the lead program Sci-B-Vac for Hepatitis B. Enrollment is proceeding well in Phase 3, which we anticipate could be complete during 2Q18. VBI still expects top-line Phase 3 data in mid-2019, which we expect to easily show non- inferiority to GSK’s Engerix-B, and which could show superiority in adults age 45 or older. Interestingly, VBI will also measure seroprotection after 2 doses of Sc-B-Vac vs 3 doses of Engerix-B, which we expect to be positive for Engerix-B as well. In our view, over the long-term, Sci-B-Vac could show a profile suggesting 2 dose protection in patients of all ages, greatly expanding the market opportunity, which we conservatively project to be $370M WW." (3/13/2018)

Are investors shorting Sangamo Therapeutics?

Sangamo Therapeutics saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 11,950,598 shares, an increase of 20.7% from the March 30th total of 9,901,110 shares. Based on an average daily volume of 2,446,250 shares, the short-interest ratio is presently 4.9 days. Approximately 14.1% of the company's shares are short sold.

Who are some of Sangamo Therapeutics' key competitors?

Some companies that are related to Sangamo Therapeutics include Bio-Techne (TECH), arGEN-X BV (ARGX), CRISPR Therapeutics (CRSP), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Editas Medicine (EDIT), REGENXBIO (RGNX) and Iovance Biotherapeutics (IOVA).

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the folowing people:

Alexander D. Macrae Ph.D., President, Chief Executive Officer, Director (Age 54)
Kathy Y. Yi, Chief Financial Officer, Senior Vice President (Age 45)
Heather D. Turner, Senior Vice President, General Counsel (Age 43)
Edward R. Conner M.D., Senior Vice President and Chief Medical Officer (Age 44)
Curt Herberts III, Senior Vice President and Chief Business Officer (Age 36)
Roger Jeffs Ph.D., Director
Joseph S. Zakrzewski, Director (Age 54)
Robert F. Carey, Independent Director (Age 58)
Stephen G. Dilly M.D. Ph.D., Independent Director (Age 57)
Steven J. Mento Ph.D., Independent Director (Age 65)

Has Sangamo Therapeutics been receiving favorable news coverage?

News articles about SGMO stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sangamo Therapeutics earned a news sentiment score of 0.21 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 45.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.68%), Wasatch Advisors Inc. (4.24%), Alexandria Capital LLC (0.87%), Nexthera Capital LP (0.77%), Wells Fargo & Company MN (0.64%) and Opaleye Management Inc. (0.61%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, Kathy Yi, Saira Ramasastry, Steven J Mento and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.

Which major investors are selling Sangamo Therapeutics stock?

SGMO stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., American Century Companies Inc., Altrinsic Global Advisors LLC, Spark Investment Management LLC, Opaleye Management Inc., Alexandria Capital LLC and Wells Fargo & Company MN. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Curt A Herberts III, Edward R Conner, Kathy Yi, Saira Ramasastry, Steven J Mento and William R Ringo. View Insider Buying and Selling for Sangamo Therapeutics.

Which major investors are buying Sangamo Therapeutics stock?

SGMO stock was acquired by a variety of institutional investors in the last quarter, including Prudential Financial Inc., UBS Group AG, Foresite Capital Management III LLC, Artal Group S.A., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Federated Investors Inc. PA and Sector Gamma AS. View Insider Buying and Selling for Sangamo Therapeutics.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $16.00.

How big of a company is Sangamo Therapeutics?

Sangamo Therapeutics has a market capitalization of $1.57 billion and generates $36.57 million in revenue each year. The biopharmaceutical company earns $-54,560,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 182 workers across the globe.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]

MarketBeat Community Rating for Sangamo Therapeutics (SGMO)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		244 (Vote Outperform)
Underperform Votes:		226 (Vote Underperform)
Total Votes:		470

MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe SGMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Sangamo Therapeutics (NASDAQ:SGMO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Sangamo Therapeutics in the last 12 months. Their average twelve-month price target is $22.20, suggesting that the stock has a possible upside of 38.75%. The high price target for SGMO is $30.00 and the low price target for SGMO is $8.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.80	2.80	2.83	2.83
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$22.20	$22.20	$19.80	$18.60
Price Target Upside:	38.75% upside	14.62% downside	20.64% downside	23.18% upside

Sangamo Therapeutics (NASDAQ:SGMO) Consensus Price Target History

Price Target History for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/13/2018	Wedbush	Reiterated Rating	Hold	$8.00	Medium
2/25/2018	Barclays	Reiterated Rating	Buy	$30.00	Low
2/23/2018	Jefferies Group	Reiterated Rating	Buy		Low
1/3/2018	Piper Jaffray Companies	Set Price Target	Buy	$25.00	High
9/5/2017	Wells Fargo & Co	Reiterated Rating	Outperform	$20.00 ➝ $30.00	Low
3/22/2017	Cowen	Reiterated Rating	Buy		High
8/4/2016	Janney Montgomery Scott	Downgrade	Buy ➝ Neutral	$15.00 ➝ $8.00	N/A

(Data available from 5/24/2016 forward)

Sangamo Therapeutics (NASDAQ:SGMO) Earnings History and Estimates Chart

Earnings by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.08)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.08)	($0.08)	($0.08)
Q2 2018	2	($0.12)	$0.03	($0.05)
Q3 2018	2	$0.03	$0.10	$0.07
Q4 2018	2	($0.07)	$0.03	($0.02)

Sangamo Therapeutics (NASDAQ SGMO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/7/2018		($0.17)					N/A
5/8/2018	Q1 2018	$0.29	($0.23)	$53.09 million	$12.60 million	View	N/A
2/22/2018	Q4 2017	($0.18)	($0.1540)	$11.10 million	$13.08 million	View	Listen
11/9/2017	Q3 2017	($0.19)	($0.15)	$10.37 million	$11.81 million	View	N/A
8/9/2017	Q2 2017	($0.23)	($0.17)	$5.82 million	$8.30 million	View	Listen
5/10/2017	Q1 2017	($0.26)	($0.23)	$4.14 million	$3.40 million	View	N/A
2/28/2017	Q416	($0.26)	($0.14)	$3.91 million	$8.90 million	View	Listen
10/26/2016	Q316	($0.25)	($0.27)	$4.24 million	$2.82 million	View	Listen
8/3/2016	Q216	($0.24)	($0.38)	$5.38 million	$3.70 million	View	N/A
5/2/2016	Q116	($0.24)	($0.23)	$5.49 million	$3.94 million	View	N/A
2/9/2016	Q415	($0.21)	($0.20)	$9.86 million	$9.10 million	View	N/A
10/28/2015	Q315	($0.25)	($0.13)	$13.09 million	$8.57 million	View	Listen
8/5/2015	Q215	($0.13)	($0.17)	$14.72 million	$8.36 million	View	Listen
4/22/2015	Q115	($0.13)	($0.08)	$12.50 million	$13.50 million	View	Listen
2/10/2015	Q414	($0.09)	($0.06)	$14.50 million	$15.00 million	View	N/A
10/22/2014	Q314	($0.04)	($0.11)	$8.27 million	$12.40 million	View	Listen
7/23/2014	Q214	($0.14)	($0.10)	$7.84 million	$10.38 million	View	Listen
5/6/2014	Q114	($0.13)	($0.12)	$6.59 million	$8.10 million	View	Listen
2/11/2014	Q413	($0.10)	($0.13)	$8.90 million	$6.90 million	View	Listen
10/23/2013	Q313	($0.11)	($0.11)	$5.52 million	$5.70 million	View	N/A
7/24/2013	Q2 2013	($0.12)	($0.10)	$4.77 million	$6.90 million	View	N/A
5/8/2013	Q1 2013	($0.17)	($0.13)	$3.79 million	$4.60 million	View	N/A
2/6/2013	Q4 2012	($0.12)	($0.07)	$5.95 million	$8.93 million	View	N/A
10/24/2012	Q312	($0.14)	($0.11)	$3.80 million	$4.90 million	View	N/A
7/25/2012		($0.15)	($0.11)			View	N/A
5/2/2012		($0.16)	($0.14)			View	N/A
2/8/2012	Q4 2011	($0.13)	($0.12)			View	N/A
10/25/2011		($0.16)	($0.18)			View	N/A
7/27/2011		($0.16)	($0.20)			View	N/A
4/26/2011		($0.17)	($0.21)			View	N/A
2/2/2011		($0.19)	($0.18)			View	N/A
10/27/2010	Q3 2010	($0.15)	($0.19)			View	N/A
7/28/2010	Q2 2010	($0.08)	($0.09)			View	N/A
5/3/2010	Q1 2010		($0.09)			View	N/A
2/3/2010	Q4 2009	($0.07)	($0.05)			View	N/A
11/4/2009	Q3 2009	($0.13)	($0.12)			View	N/A
7/29/2009	Q2 2009	($0.15)	($0.11)			View	N/A
4/29/2009	Q1 2009	($0.10)	($0.17)			View	N/A
2/4/2009	Q4 2008	($0.15)	($0.06)			View	N/A
10/29/2008	Q3 2008	($0.17)	($0.15)			View	N/A
7/23/2008	Q2 2008	($0.17)	($0.18)			View	N/A
4/30/2008	Q1 2008	($0.16)	($0.20)			View	N/A
2/5/2008	Q4 2007	($0.12)	($0.17)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Sangamo Therapeutics (NASDAQ:SGMO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Sangamo Therapeutics (NASDAQ SGMO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 56.37%

Insider Trading History for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ SGMO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/15/2018	Kathy Yi	CFO	Sell	5,000	$15.38	$76,900.00	12,250
5/7/2018	Edward R. Conner	VP	Sell	5,000	$16.36	$81,800.00
4/16/2018	Kathy Yi	CFO	Sell	5,000	$19.83	$99,150.00	12,250
4/13/2018	Curt A Herberts III	VP	Sell	8,163	$20.00	$163,260.00	22,788
4/6/2018	Edward R. Conner	VP	Sell	5,000	$17.41	$87,050.00
4/2/2018	Curt A Herberts III	VP	Sell	2,278	$18.30	$41,687.40
4/2/2018	Steven J Mento	Director	Sell	7,215	$18.40	$132,756.00
3/15/2018	Kathy Yi	CFO	Sell	5,000	$25.56	$127,800.00	12,250
3/6/2018	Edward R. Conner	VP	Sell	5,000	$24.78	$123,900.00
3/1/2018	Curt A Herberts III	VP	Sell	15,000	$23.06	$345,900.00	14,796
3/1/2018	Steven J Mento	Director	Sell	9,433	$23.27	$219,505.91	8,480
2/26/2018	Saira Ramasastry	Director	Sell	9,450	$24.88	$235,116.00	9,450
2/6/2018	Edward R. Conner	VP	Sell	5,000	$18.49	$92,450.00
2/1/2018	Curt A Herberts III	VP	Sell	15,000	$20.59	$308,850.00	29,625
2/1/2018	Steven J Mento	Director	Sell	11,520	$20.59	$237,196.80	5,000
1/8/2018	Edward R. Conner	VP	Sell	5,000	$17.11	$85,550.00
1/3/2018	Curt A Herberts III	VP	Sell	15,000	$17.26	$258,900.00	13,015
12/6/2017	Edward R Conner	VP	Sell	5,000	$16.24	$81,200.00	5,000
12/4/2017	Curt A Herberts III	VP	Sell	11,803	$18.00	$212,454.00	27,636
12/1/2017	Curt A. Herberts III	VP	Sell	16,630	$16.13	$268,241.90
11/17/2017	Saira Ramasastry	Director	Sell	5,000	$14.67	$73,350.00	5,000
10/2/2017	Curt A Herberts III	VP	Sell	15,000	$15.25	$228,750.00
9/20/2017	William R Ringo	Director	Sell	31,000	$14.37	$445,470.00	31,800
9/1/2017	Curt A Herberts III	VP	Sell	15,000	$15.00	$225,000.00	15,833
8/14/2017	Curt A Herberts III	VP	Sell	11,474	$10.44	$119,788.56	23,991
7/14/2017	Curt A Herberts III	VP	Sell	15,000	$10.00	$150,000.00	35,517
6/1/2017	Curt A. Herberts III	VP	Sell	2,000	$6.80	$13,600.00
5/12/2017	Curt A. Herberts III	VP	Sell	2,639	$8.02	$21,164.78
8/1/2015	Ra Capital Management, Llc	Major Shareholder	Sell	27,770	$12.82	$356,011.40
7/30/2015	Ra Capital Management, Llc	Major Shareholder	Sell	109,590	$12.42	$1,361,107.80
7/29/2015	Ra Capital Management, Llc	Major Shareholder	Sell	1,407	$12.41	$17,460.87
7/28/2015	Ra Capital Management, Llc	Major Shareholder	Sell	60,081	$12.11	$727,580.91
7/25/2015	Ra Capital Management, Llc	Major Shareholder	Sell	47,429	$12.31	$583,850.99
7/24/2015	Ra Capital Management, Llc	Major Shareholder	Sell	124,050	$12.28	$1,523,334.00
7/17/2015	Ra Capital Management, Llc	Major Shareholder	Buy	37,215	$12.26	$456,255.90
7/15/2015	Edward O Lanphier II	CEO	Sell	25,000	$10.43	$260,750.00
7/13/2015	Henry Ward Wolff	CFO	Sell	12,000	$10.00	$120,000.00
7/1/2015	Ra Capital Management, Llc	Major Shareholder	Sell	82,700	$16.01	$1,324,027.00
6/16/2015	Ra Capital Management, Llc	Major Shareholder	Sell	250,500	$16.55	$4,145,775.00
6/9/2015	Ra Capital Management, Llc	Major Shareholder	Sell	83,500	$15.50	$1,294,250.00
6/6/2015	Ra Capital Management, Llc	Major Shareholder	Sell	135,101	$14.29	$1,930,593.29
6/5/2015	Dale G Ando	CMO	Sell	15,000	$12.29	$184,350.00
6/5/2015	Ra Capital Management, Llc	Major Shareholder	Sell	115,102	$14.13	$1,626,391.26
6/4/2015	Ra Capital Management, Llc	Major Shareholder	Sell	70,640	$13.10	$925,384.00
6/3/2015	Ra Capital Management, Llc	Major Shareholder	Sell	76,833	$12.86	$988,072.38
6/3/2015	William R Ringo	Director	Sell	2,200	$12.44	$27,368.00
6/1/2015	Philip D Gregory	SVP	Sell	15,000	$12.39	$185,850.00
5/30/2015	Ra Capital Management, Llc	Major Shareholder	Sell	65,884	$13.40	$882,845.60
5/29/2015	Ra Capital Management, Llc	Major Shareholder	Sell	155,675	$13.53	$2,106,282.75
5/28/2015	Ra Capital Management, Llc	Major Shareholder	Sell	148,689	$13.43	$1,996,893.27
5/27/2015	Ra Capital Management, Llc	Major Shareholder	Sell	263,437	$13.55	$3,569,571.35
5/23/2015	Ra Capital Management, Llc	Major Shareholder	Sell	51,597	$13.27	$684,692.19
5/22/2015	Ra Capital Management, Llc	Major Shareholder	Sell	56,396	$13.56	$764,729.76
5/13/2015	Ra Capital Management, Llc	Major Shareholder	Sell	56,060	$13.12	$735,507.20
5/12/2015	Ra Capital Management, Llc	Major Shareholder	Sell	29,659	$13.03	$386,456.77
5/8/2015	Ra Capital Management, Llc	Major Shareholder	Sell	83,300	$12.40	$1,032,920.00
5/7/2015	Ra Capital Management, Llc	Major Shareholder	Buy	35,736	$12.09	$432,048.24
5/5/2015	Dale G Ando	CMO	Sell	15,000	$12.29	$184,350.00
5/4/2015	William R Ringo	Director	Sell	3,000	$12.98	$38,940.00
4/30/2015	Ra Capital Management, Llc	Major Shareholder	Buy	124,500	$13.45	$1,674,525.00
4/28/2015	Ra Capital Management, Llc	Major Shareholder	Buy	74,844	$13.29	$994,676.76
4/25/2015	Ra Capital Management, Llc	Major Shareholder	Buy	166,000	$13.63	$2,262,580.00
4/22/2015	Ra Capital Management, Llc	Major Shareholder	Sell	352,750	$14.86	$5,241,865.00
4/17/2015	Ra Capital Management, Llc	Major Shareholder	Buy	41,500	$14.02	$581,830.00
4/16/2015	Ra Capital Management, Llc	Major Shareholder	Sell	21,829	$14.09	$307,570.61
4/15/2015	Edward O Lanphier II	CEO	Sell	25,000	$15.33	$383,250.00
4/15/2015	Ra Capital Management, Llc	Major Shareholder	Buy	21,829	$13.16	$287,269.64
4/14/2015	Ra Capital Management, Llc	Major Shareholder	Sell	3,055	$14.78	$45,152.90
4/11/2015	Ra Capital Management, Llc	Major Shareholder	Buy	116,992	$14.48	$1,694,044.16
4/10/2015	Henry Ward Wolff	CFO	Sell	12,000	$15.31	$183,720.00
4/10/2015	Ra Capital Management, Llc	Major Shareholder	Buy	83,000	$14.91	$1,237,530.00
4/9/2015	Ra Capital Management, Llc	Major Shareholder	Sell	69,856	$16.27	$1,136,557.12
4/8/2015	Ra Capital Management, Llc	Major Shareholder	Buy	121,876	$15.49	$1,887,859.24
4/7/2015	Ra Capital Management, Llc	Major Shareholder	Buy	33,667	$15.42	$519,145.14
4/6/2015	Dale G Ando	CMO	Sell	15,000	$14.94	$224,100.00
4/6/2015	William R Ringo	Director	Sell	2,200	$14.95	$32,890.00
4/4/2015	Ra Capital Management, Llc	Major Shareholder	Buy	179,031	$15.38	$2,753,496.78
4/3/2015	Ra Capital Management, Llc	Major Shareholder	Buy	195,126	$16.61	$3,241,042.86
4/1/2015	Philip D Gregory	SVP	Sell	15,000	$15.15	$227,250.00
4/1/2015	Ra Capital Management, Llc	Major Shareholder	Sell	250,000	$18.01	$4,502,500.00
3/28/2015	Ra Capital Management, Llc	Major Shareholder	Buy	84,000	$17.10	$1,436,400.00
3/27/2015	Ra Capital Management, Llc	Major Shareholder	Buy	256,187	$17.65	$4,521,700.55
3/26/2015	Ra Capital Management, Llc	Major Shareholder	Buy	210,013	$18.14	$3,809,635.82
3/25/2015	Ra Capital Management, Llc	Major Shareholder	Buy	84,000	$19.42	$1,631,280.00
3/21/2015	Ra Capital Management, Llc	Major Shareholder	Buy	101,808	$21.22	$2,160,365.76
3/19/2015	Henry Ward Wolff	CFO	Sell	10,000	$18.00	$180,000.00
3/19/2015	Ra Capital Management, Llc	Major Shareholder	Sell	17,808	$24.28	$432,378.24
3/18/2015	Ra Capital Management, Llc	Major Shareholder	Sell	84,000	$23.74	$1,994,160.00
3/17/2015	Ra Capital Management, Llc	Major Shareholder	Buy	52,161	$23.02	$1,200,746.22
3/16/2015	Edward O Lanphier II	CEO	Sell	25,000	$17.29	$432,250.00
3/13/2015	Ra Capital Management, Llc	Major Shareholder	Buy	71,319	$22.76	$1,623,220.44
3/12/2015	Ra Capital Management, Llc	Major Shareholder	Sell	123,480	$23.40	$2,889,432.00
3/10/2015	Ra Capital Management, Llc	Major Shareholder	Buy	12,522	$22.30	$279,240.60
3/7/2015	Ra Capital Management, Llc	Major Shareholder	Buy	258,377	$22.25	$5,748,888.25
3/6/2015	Ra Capital Management, Llc	Major Shareholder	Sell	61,483	$24.10	$1,481,740.30
3/3/2015	Ra Capital Management, Llc	Major Shareholder	Sell	84,000	$18.21	$1,529,640.00
3/3/2015	William R Ringo	Director	Sell	2,200	$17.21	$37,862.00
3/2/2015	Philip D Gregory	SVP	Sell	15,000	$17.26	$258,900.00
2/28/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$18.10	$760,200.00
2/27/2015	Ra Capital Management, Llc	Major Shareholder	Sell	32,196	$19.37	$623,636.52
2/26/2015	Ra Capital Management, Llc	Major Shareholder	Buy	74,194	$19.57	$1,451,976.58
2/20/2015	Ra Capital Management, Llc	Major Shareholder	Sell	35,319	$18.40	$649,869.60
2/19/2015	Ra Capital Management, Llc	Major Shareholder	Sell	6,720	$18.51	$124,387.20
2/18/2015	Ra Capital Management, Llc	Major Shareholder	Sell	11,172	$18.11	$202,324.92
2/14/2015	Ra Capital Management, Llc	Major Shareholder	Sell	15,380	$18.61	$286,221.80
2/13/2015	Ra Capital Management, Llc	Major Shareholder	Sell	15,409	$18.46	$284,450.14
2/12/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$18.04	$757,680.00
2/12/2015	Saira Ramasastry	Director	Sell	10,000	$15.00	$150,000.00
2/11/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$19.65	$825,300.00
2/7/2015	Ra Capital Management, Llc	Major Shareholder	Sell	34,688	$18.52	$642,421.76
2/6/2015	Ra Capital Management, Llc	Major Shareholder	Sell	7,312	$18.42	$134,687.04
2/5/2015	Dale G Ando	CMO	Sell	15,000	$12.93	$193,950.00
2/5/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$18.23	$765,660.00
2/3/2015	William R Ringo	Director	Sell	2,200	$12.70	$27,940.00
2/2/2015	Philip D Gregory	SVP	Sell	15,000	$12.86	$192,900.00
1/16/2015	Edward O Lanphier II	CEO	Sell	25,000	$14.22	$355,500.00
1/12/2015	Henry Ward Wolff	CFO	Sell	12,000	$15.87	$190,440.00
1/5/2015	Dale G Ando	CMO	Sell	15,000	$15.19	$227,850.00
1/5/2015	William R Ringo	Director	Sell	2,200	$15.20	$33,440.00
12/15/2014	Edward O Lanphier II	CEO	Sell	25,000	$15.40	$385,000.00
12/15/2014	John William Larson	Director	Sell	10,000	$16.28	$162,800.00
12/9/2014	John William Larson	Director	Sell	10,000	$12.00	$120,000.00
12/1/2014	Philip D Gregory	SVP	Sell	15,000	$11.68	$175,200.00
11/17/2014	Edward O Lanphier II	CEO	Sell	25,000	$11.23	$280,750.00
11/12/2014	John William Larson	Director	Sell	10,000	$12.00	$120,000.00
11/3/2014	Philip D Gregory	SVP	Sell	15,000	$11.91	$178,650.00
10/28/2014	John William Larson	Director	Sell	10,000	$12.02	$120,200.00
10/10/2014	Henry Ward Wolff	CFO	Sell	2,000	$10.10	$20,200.00
10/6/2014	Dale G Ando	CMO	Sell	15,000	$10.72	$160,800.00
10/1/2014	Philip D Gregory	SVP	Sell	15,000	$10.80	$162,000.00
9/15/2014	Edward O Lanphier II	CEO	Sell	25,000	$12.14	$303,500.00
9/10/2014	Henry Ward Wolff	CFO	Sell	2,000	$12.31	$24,620.00
9/5/2014	Dale G Ando	CMO	Sell	15,000	$12.20	$183,000.00
9/4/2014	John William Larson	Director	Sell	10,000	$12.81	$128,100.00
8/15/2014	Edward O Lanphier II	CEO	Sell	25,000	$13.95	$348,750.00
8/11/2014	Henry Ward Wolff	CFO	Sell	10,000	$14.17	$141,700.00
8/5/2014	Dale G Ando	CMO	Sell	15,000	$12.99	$194,850.00
8/4/2014	John William Larson	Director	Sell	10,000	$12.56	$125,600.00
8/1/2014	Philip D Gregory	SVP	Sell	15,000	$12.54	$188,100.00
7/18/2014	Edward O Lanphier II	CEO	Sell	25,000	$12.16	$304,000.00
7/10/2014	Henry Ward Wolff	CFO	Sell	15,000	$13.26	$198,900.00
7/1/2014	Philip D Gregory	SVP	Sell	15,000	$15.66	$234,900.00
6/23/2014	Saira Ramasastry	Director	Sell	5,550	$15.53	$86,191.50
6/16/2014	Edward O Lanphier II	CEO	Sell	25,000	$16.41	$410,250.00
6/10/2014	Henry Ward Wolff	CFO	Sell	15,000	$15.62	$234,300.00
6/2/2014	Philip D Gregory	SVP	Sell	15,000	$12.85	$192,750.00
5/15/2014	Edward Lanphier II	CEO	Sell	25,000	$13.14	$328,500.00	295,000
5/1/2014	Philip Gregory	SVP	Sell	15,000	$13.68	$205,200.00	109,347
4/28/2014	Dale Ando	CMO	Sell	15,000	$13.64	$204,600.00	97,015
4/28/2014	John William Larson	Director	Sell	10,000	$13.48	$134,800.00	218,160
4/15/2014	Edward Lanphier II	CEO	Sell	25,000	$14.20	$355,000.00	295,000
4/10/2014	Henry Ward Wolff	CFO	Sell	15,000	$15.72	$235,800.00	225,347
3/26/2014	Dale Ando	CMO	Sell	15,000	$18.65	$279,750.00	97,015
3/21/2014	Philip Gregory	Insider	Sell	15,000	$22.38	$335,700.00	109,347
3/17/2014	Edward Lanphier II	CEO	Sell	50,000	$23.22	$1,161,000.00	295,000
3/17/2014	Saira Ramasastry	Director	Sell	10,000	$23.26	$232,600.00
3/14/2014	Steven Mento	Director	Sell	6,103	$22.77	$138,965.31	23,563
2/18/2014	Edward Lanphier II	CEO	Sell	50,000	$18.09	$904,500.00	295,000
1/27/2014	Dale Ando	CMO	Sell	15,000	$18.58	$278,700.00	97,015
1/10/2014	Henry Ward Wolff	CFO	Sell	10,000	$18.69	$186,900.00	227,347
1/2/2014	Philip Gregory	VP	Sell	15,000	$13.56	$203,400.00	109,347
12/26/2013	Dale Ando	CMO	Sell	15,000	$14.37	$215,550.00	97,015
11/15/2013	Edward Lanphier II	CEO	Sell	25,000	$10.11	$252,750.00	330,000
11/5/2013	Philip D Gregory	VP	Sell	15,000	$9.60	$144,000.00
10/28/2013	Dale G Ando	CMO	Sell	15,000	$10.39	$155,850.00
10/21/2013	Paul B Cleveland	Director	Sell	10,000	$10.93	$109,300.00
10/15/2013	Edward O Lanphier II	CEO	Sell	25,000	$11.32	$283,000.00
10/10/2013	Henry Ward Wolff	CFO	Sell	10,000	$11.28	$112,800.00	209,219
10/1/2013	Philip D Gregory	VP	Sell	15,000	$10.54	$158,100.00
9/16/2013	Edward Lanphier II	CEO	Sell	25,000	$11.29	$282,250.00	330,000
9/10/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.86	$108,600.00
9/3/2013	Paul Cleveland	Director	Sell	7,278	$10.30	$74,963.40
9/3/2013	Philip Gregory	VP	Sell	15,000	$10.33	$154,950.00	90,000
8/26/2013	Dale Ando	CMO	Sell	15,000	$10.04	$150,600.00	84,798
8/15/2013	Edward Lanphier II	CEO	Sell	25,000	$10.12	$253,000.00	330,000
8/13/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.00	$100,000.00	209,219
8/1/2013	Philip Gregory	VP	Sell	15,000	$9.89	$148,350.00	90,000
7/29/2013	Philip D Gregory	VP	Sell	15,000	$10.04	$150,600.00
7/26/2013	Dale G Ando	CMO	Sell	15,000	$10.09	$151,350.00
7/17/2013	Edward O Lanphier II	CEO	Sell	25,000	$10.00	$250,000.00
7/17/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.00	$100,000.00
7/15/2013	Paul B Cleveland	Director	Sell	8,000	$9.59	$76,720.00
6/3/2013	Philip D Gregory	VP	Sell	3,000	$7.88	$23,640.00
5/28/2013	Dale G Ando	CMO	Sell	15,000	$8.32	$124,800.00
4/10/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.00	$100,000.00
12/26/2012	Dale G Ando	CMO	Sell	17,000	$5.92	$100,640.00
12/3/2012	John William Larson	Director	Sell	15,000	$5.64	$84,600.00
9/5/2012	Dale G Ando	CMO	Sell	15,000	$5.60	$84,000.00
9/4/2012	John William Larson	Director	Sell	15,000	$5.30	$79,500.00

(Data available from 1/1/2013 forward)

Sangamo Therapeutics (NASDAQ SGMO) News Headlines

Source:

Date	Headline
	Sangamo Therapeutics Inc (SGMO) CFO Kathy Yi Sells 5,000 Shares www.americanbankingnews.com - May 16 at 8:35 PM
	Sangamo Therapeutics (SGMO) Downgraded to Strong Sell at Zacks Investment Research www.americanbankingnews.com - May 16 at 3:45 PM
	BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003 www.reuters.com - May 16 at 8:31 AM
	Sangamo Therapeutics (SGMO) & Sanofi (SNY) Company, Bioverativ Inc., Report FDA Acceptance of IND Application ... www.streetinsider.com - May 16 at 8:31 AM
	Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease finance.yahoo.com - May 16 at 8:31 AM
	Q2 2018 EPS Estimates for Sangamo Therapeutics Inc Decreased by Jefferies Group (SGMO) www.americanbankingnews.com - May 14 at 1:43 AM
	DBV Technologies (DBVT) vs. Sangamo Therapeutics (SGMO) Financial Comparison www.americanbankingnews.com - May 14 at 1:19 AM
	Zacks: Analysts Anticipate Sangamo Therapeutics Inc (SGMO) Will Post Quarterly Sales of $27.58 Million www.americanbankingnews.com - May 12 at 3:50 AM
	Sangamo Therapeutics Inc (SGMO) to Post Q3 2018 Earnings of $0.10 Per Share, Jefferies Group Forecasts www.americanbankingnews.com - May 11 at 10:07 AM
	Zacks Investment Research Downgrades Sangamo Therapeutics (SGMO) to Hold www.americanbankingnews.com - May 10 at 7:05 PM
	Sangamo Therapeutics Inc (SGMO) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - May 10 at 4:37 PM
	-$0.07 Earnings Per Share Expected for Sangamo Therapeutics Inc (SGMO) This Quarter www.americanbankingnews.com - May 10 at 9:22 AM
	Edited Transcript of SGMO earnings conference call or presentation 8-May-18 12:00pm GMT finance.yahoo.com - May 10 at 8:34 AM
	Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 5,000 Shares of Stock www.americanbankingnews.com - May 9 at 8:28 PM
	Applied Genetic Technologies (AGTC) vs. Sangamo Therapeutics (SGMO) Head-To-Head Contrast www.americanbankingnews.com - May 9 at 3:13 AM
	Sangamo Therapeutics' (SGMO) CEO Sandy Macrae on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 8 at 5:29 PM
	Sangamo Therapeutics (SGMO) Cut to Buy at ValuEngine www.americanbankingnews.com - May 8 at 3:29 PM
	Sangamo Therapeutics (SGMO) Announces Earnings Results, Misses Estimates By $0.07 EPS www.americanbankingnews.com - May 8 at 2:43 PM
	Sangamo Therapeutics misses by $0.05, misses on revenue seekingalpha.com - May 8 at 8:27 AM
	Sangamo: The Secondary Was Ill-Timed Or Not seekingalpha.com - May 8 at 8:27 AM
	Sangamo: 1Q Earnings Snapshot finance.yahoo.com - May 8 at 8:27 AM
	Sangamo Therapeutics Reports First Quarter 2018 Financial Results finance.yahoo.com - May 8 at 8:27 AM
	Sangamo Therapeutics Announces Senior Leadership Changes finance.yahoo.com - May 3 at 5:16 PM
	Sangamo Therapeutics (SGMO) Upgraded to "Strong-Buy" at ValuEngine www.americanbankingnews.com - May 2 at 11:39 PM
	Sangamo Therapeutics Announces First Quarter 2018 Conference Call and Webcast finance.yahoo.com - May 1 at 5:10 PM
	Sangamo Therapeutics (SGMO) Upgraded to "Buy" by Zacks Investment Research www.americanbankingnews.com - May 1 at 10:02 AM
	Sangamo Therapeutics Announces Presentations At 2018 Annual Meeting Of The American Society Of Gene & Cell Therapy finance.yahoo.com - May 1 at 8:35 AM
	Sangamo Therapeutics (SGMO) Downgraded by BidaskClub to "Sell" www.americanbankingnews.com - May 1 at 8:03 AM
	Sangamo Therapeutics (SGMO) Set to Announce Earnings on Tuesday www.americanbankingnews.com - May 1 at 5:18 AM
	Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares finance.yahoo.com - April 30 at 5:07 PM
	Has Sangamo Therapeutics (SGMO) Outpaced Other Medical Stocks This Year? finance.yahoo.com - April 30 at 5:07 PM
	Sangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat ... www.prnewswire.com - April 29 at 8:35 AM
	Sangamo: The Secondary Was Ill-Timed-Or Not seekingalpha.com - April 28 at 5:07 PM
	Comparing Solid Biosciences (SLDB) & Sangamo Therapeutics (SGMO) www.americanbankingnews.com - April 28 at 9:29 AM
	Sangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Transfusion-Dependent Beta-Thalassemia finance.yahoo.com - April 27 at 8:41 AM
	Sangamo Therapeutics Inc (SGMO) Short Interest Up 20.7% in April www.americanbankingnews.com - April 26 at 2:22 AM
	Watch CRISPR Therapeutics (CRSP) www.baystreet.ca - April 25 at 8:28 AM
	Sangamo Therapeutics (SGMO) Commences $200M Public Offering of Common Stock www.streetinsider.com - April 25 at 8:28 AM
	$36.08 Million in Sales Expected for Sangamo Therapeutics Inc (SGMO) This Quarter www.americanbankingnews.com - April 25 at 5:56 AM
	Your Guide to Investing in Zinc-Finger (ZFN) Gene Editing finance.yahoo.com - April 24 at 5:28 PM
	Sangamo Therapeutics Announces Proposed Public Offering of Common Stock finance.yahoo.com - April 24 at 5:28 PM
	Sangamo Therapeutics shares fall on announced secondary offering finance.yahoo.com - April 24 at 5:28 PM
	Sangamo Therapeutics Inc (SGMO) Expected to Post Earnings of -$0.05 Per Share www.americanbankingnews.com - April 23 at 1:14 AM
	BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior ... www.reuters.com - April 19 at 5:31 PM
	Reader Inquiry: Is Recent Weakness In Sangamo Therapeutics A Buying Opportunity? seekingalpha.com - April 19 at 8:26 AM
	Insider Selling: Sangamo Therapeutics Inc (SGMO) CFO Sells 5,000 Shares of Stock www.americanbankingnews.com - April 18 at 4:10 PM
	Curt A. Herberts III Sells 8,163 Shares of Sangamo Therapeutics Inc (SGMO) Stock www.americanbankingnews.com - April 17 at 7:28 PM
	Sangamo Therapeutics Inc (SGMO) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - April 15 at 11:29 AM
	Has Sangamo Therapeutics Inc (NASDAQ:SGMO) Improved Earnings Growth In Recent Times? finance.yahoo.com - April 13 at 8:35 AM
	Markets Recovering From Latest Trump Tweetstorm finance.yahoo.com - April 11 at 5:19 PM

Sangamo Therapeutics (NASDAQ:SGMO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Sangamo Therapeutics (NASDAQ:SGMO) Income Statement, Balance Sheet and Cash Flow Statement

Sangamo Therapeutics (NASDAQ SGMO) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff